|
|
|
| Differential expression of microRNA in atypical endometrial hyperplasia based on high-throughput sequencing |
| TANG Shiqian CHU Chunfang LI Ting ZHENG Ping ZHOU Qi LIU Juhong WANG Yu▲ |
| Department of Gynecology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, China |
|
|
|
Abstract Objective To investigate the differentially expressed microRNAs (miRNAs) and significance in endometrium from atypical endometrial hyperplasia (AEH) and normal women through high-throughput sequencing. Methods From January 2016 to January 2017, three patients diagnosed with AEH (experimental group) and three normal women (control group) admitted to Beijing Obstetrics and Gynecology Hospital, Capital Medical University were collected. Second-generation high-throughput sequencing was used to screen the differentially expressed miRNAs. Databases was used to predict its target genes and biological functions, and understand the closely related miRNAs and their co-regulated target genes. Results There were 18 differentially expressed miRNAs in two groups, which 17 were up-regulated and 1 was down-regulated. Most of the target genes with differential miRNA were concentrated in the signal transduction pathways related to cancer or body metabolism. Among the differentially expressed miRNAs, miR-577, miR-182-5p and miR-4286 are closely linked. They co-regulate the expressions of CACNA1C, MECP2, FOXK1, LPP, SH3TC2, Smad and MDM4. Conclusion There are significantly differential expressions of miRNAs in endometrium from AEH and Normal endometrial tissue. These miRNAs may be involved in the occurrence and development of AEH via adjusting different target genes to regulate the signal pathway.
|
|
|
|
|
|
[1] Denny L，Quinn M. FIGO cancer report 2015 [J]. Int J Gynaecol Obstet，2015，131（Suppl 2）：S75.
[2] Lee H，Choi HJ，Kang CS，et al. Expression of miRNAs and PTEN in endometrial specimens ranging from histologically normal to hyperplasia and endometrial adenocarcinoma [J]. Mod Pathol，2012，25（11）：1508-1515.
[3] Bartel DP. MicroRNAs：genomics，biogenesis，mechanism，and function [J].Cell，2004，116（2）：281-297.
[4] Qin Y，Yu Z，Yang J，et al. Oral progestin treatment for early-stage endometrial cancer： a systematic review and meta-analysis [J]. Int J Gynecol Cancer，2016，26（6）：1081-1091.
[5] Koh WJ，Abu-Rustum NR，Bean S，et al. Uterine Neoplasms，Version 1. 2018， NCCN Clinical Practice Guidelines in Oncology [J]. J Natl Compr Canc Netw，2018，16（2）：170-199.
[6] Shan W，Wang C，Zhang Z，et al. Conservative therapy with metformin plus megestrol acetate for endometrial atypical hyperplasia [J]. J Gynecol Oncol，2014，25（3）：214-220.
[7] Beyer C，Zampetaki A，Lin NY，et al. Signature of circulating microRNAs in osteoarthritis [J]. Ann Rheum Dis，2015， 74（3）：e18.
[8] Ha M，Kim VN. Regulation of microRNA biogenesis [J]. Nat Rev Mol Cell Biol，2014，15（8）：509-524.
[9] Chen H，Fan Y，Xu W，et al. Exploration of miR-1202 and miR-196a in human endometrial cancer based on high throughout gene screening analysis [J]. Oncol Rep，2017，37（6）：3493-3501.
[10] Zhang G，Hou X，Li Y，et al. miR-205 inhibits cell apoptosis by targeting phosphatase and tensin homolog deleted on chromosome ten in endometrial cancer ishikawa cells [J]. BMC Cancer，2014，14：440.
[11] Zhao ZN，Bai JX，Zhou Q，et al. TSA suppresses miR-106b-93-25 cluster expression through downregulation of MYC and inhibits proliferation and induces apoptosis in human EMC [J]. PLoS One，2012，7（9）：e45 133.
[12] Giglio S，Annibali V，Cirombella R，et al. miRNAs as Candidate Biomarker for the Accurate Detection of Atypical Endometrial Hyperplasia/Endometrial Intraepithelial Neo-plasia [J]. Front Oncol，2019，9：526.
[13] Tsuchiyama K，Ito H，Taga M，et al. Expression of microRNAs associated with Gleason grading system in prostate cancer：miR-182-5p is a useful marker for high grade prostate cancer [J]. Prostate，2013，73（8）：827-834.
[14] Li Y，Chen S，Shan Z，et al. miR-182-5p improves the viability，mitosis，migration，and invasion ability of human gastric cancer cells by down-regulating RAB27A [J]. Biosci Rep，2017，37（3）.
[15] Ling C，Wang X，Zhu J，et al. MicroRNA-4286 promotes cell proliferation， migration， and invasion via PTEN regulation of the PI3K/Akt pathway in non-small cell lung cancer [J]. Cancer Med，2019，8（7）：3520-3531.
[16] Zhang M，Tian H，Li R，et al. MicroRNA-4286 promotes esophageal carcinoma development by targeting INPP4A to evoke the JAK2/STAT3 pathway activation [J]. Pharmazie，2018，73（6）：342-348.
[17] Luo Y，Wu J，Wu Q，et al. miR-577 Regulates TGF-β Induced Cancer Progression through a SDPR-Modulated Positive-Feedback Loop with ERK-NF-κB in Gastric Cancer [J]. Mol Ther，2019，27（6）：1166-1182.
[18] 刘贵鹏，王东娇，等. Smad 2/3和Smad 4在子宫内膜癌中的表达及其相关性[J].中国医科大学学报，2010，39（7）：546-548.
[19] Hirata H，Ueno K，Shahryari V，et al. Oncogenic miRNA-182-5p targets Smad4 and RECK in human bladder cancer [J]. PLoS One，2012，7（11）：e51 056.
[20] Shackelford DB，Shaw RJ. The LKB1-AMPK pathway： metabolism and growth control in tumour suppression [J]. Nat Rev Cancer，2009，9（8）：563-575.
[21] Chen XY，Li GM，Dong Q，et al. MiR-577 inhibits pancreatic β-cell function and survival by targeting fibroblast growth factor 21（FGF-21）in pediatric diabetes [J]. Genet Mol Res，2015，14（4）：15 462-15 470. |
|
|
|
